First US Eliquis Generics Face Six-Year Wait
Mylan And Micro Labs Have Settled With BMS Over Apixaban
Mylan and Micro Labs have received the first FDA approvals for generic rivals to BMS’ Eliquis oral anticoagulant. However, as a result of the firms’ settlements with the originator, BMS does not expect the generics to hit the US market until 2026.
You may also be interested in...
The High Court of Delhi has issued a temporary injunction blocking four Indian drug-makers from launching generic versions of Bristol-Myers’ top-selling anticoagulant apixaban.
Armas has kicked off 2020 with the launch of four generic injectables in the US.
While Sandoz looks for a new country head in Germany, Lupin has appointed a new chief corporate development officer and a Coherus executive has left the firm.